# AnaCardio funding rounds and investors

As of 19 Nov 2026, AnaCardio has raised $71.0M across 1 verified round on record (amounts in other currencies converted to USD); latest: EUR 62.5m Series B led by Ljungström family office and Novo Holdings, announced 29 Sep 2026.

A clinical-stage biopharmaceutical company developing novel therapies for heart failure

Website: https://anacardio.com  
Headquarters: Stockholm, Sweden  
Page: https://fireround.dev/companies/anacardio

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-09-29 | Series B | EUR 62.5m | Ljungström family office, Novo Holdings | Flerie, Helsinn, Industrifonden, Innovestor Life Science Fund, LLD Nybohov Invest AB, Pureos Bioventures, Sound Bioventures | [anacardio.com](https://anacardio.com/anacardio-raises-e62-5-million-series-b-financing-to-advance-transformational-novel-therapy-in-heart-failure-towards-phase-3-readiness), [globenewswire.com](https://www.globenewswire.com/news-release/2026/09/30/3371523/0/en/anacardio-raises-62-5-million-series-b-financing-to-advance-transformational-novel-therapy-in-heart-failure-towards-phase-3-readiness.html), [globenewswire.com](https://www.globenewswire.com/news-release/2026/09/30/3371728/0/en/anacardio-raises-62-5-million-series-b-financing-to-advance-transformational-novel-therapy-in-heart-failure-towards-phase-3-readiness.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
